Clinical Trial Update: Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating targeted Vitamin D treatment for schizophrenia-associated hyperprolinemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Vitamin D (Cholecalciferol)

Snippet

Sponsor: NYU Langone Health | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: WITHDRAWN